domingo, 30 de julio de 2017

Impact of a 21-Gene Recurrence Score Test on the Choice of Adjuvant Chemotherapy for Hormone Receptor-positive Early-stage Breast Cancer: A Prospec... - PubMed - NCBI

Impact of a 21-Gene Recurrence Score Test on the Choice of Adjuvant Chemotherapy for Hormone Receptor-positive Early-stage Breast Cancer: A Prospec... - PubMed - NCBI



 2017 Aug;37(8):4539-4547.

Impact of a 21-Gene Recurrence Score Test on the Choice of Adjuvant Chemotherapy for Hormone Receptor-positive Early-stage Breast Cancer: A Prospective Study.

Zeng Y1Li Q1Qin T2Li S1Jin L1Wu J1Chen K1Deng H1Rao N1Liu Q1Su F1Jia W3Yao H3,2.

Abstract

BACKGROUND:

Studies have recommended a 21-gene recurrence score (RS) to optimize adjuvant treatment for patients with early-stage breast cancer (EBC) with hormone receptor-positive (HR+) and human epidermal growth factor receptor-2 negative (HER2-) tumors. This study aimed to prospectively evaluate the impact of this RS in Chinese patients with breast cancer.

PATIENTS AND METHODS:

We prospectively collected 227 patients with EBC with estrogen receptor-positive (ER+) and HER2- tumors. We used one-way analysis of variance to compare the distribution of different risk groups based on a 21-gene RS assay. A Kruskal-Wallis test and either a chi-square or Fisher's exact test were used as appropriate to compare continuous and categorical variables, respectively.

RESULTS:

Of the 227 eligible women enrolled, 61.2%, 30%, and 8.8% of patients were in the low (≤17), intermediate (18-30) and high (≥31) RS groups, respectively. Of the patients with a low RS, 74.8% were overestimated into the intermediate-risk group by St. Gallen risk. The overall impact of the 21-gene RS was reduced use of chemotherapy (78/227, 34.4%). In addition, Ki67 expression was positively associated with the 21-gene RS (R=0.68).

CONCLUSION:

Among patients with ER+/HER2- EBC, the 21-gene RS was an effective method for making a chemotherapy decision. Ki67 was associated with 21-gene RS.

KEYWORDS:

21-gene score; Breast cancer; Ki67; adjuvant chemotherapy; early stage

PMID:
 
28739750

No hay comentarios:

Publicar un comentario